The nominal deal value is $11.5B, including assumption of debt.
TMO seems willing to acquire almost any company in the life-sciences industry. It may be a bit too much like Valeant and Tyco for my taste. (No position.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”